HCG

Intro

Human Chorionic Gonadotropin (HCG) is a glycoprotein hormone with a molecular weight of approximately 36.7 kDa, naturally produced by the placental syncytiotrophoblasts within days of fertilization.

Its alpha subunit (92 amino acids) is structurally identical to the alpha chains of LH, FSH, and TSH. Its unique beta subunit carries 80-85% homology to LH with an additional 24-amino-acid carboxy-terminal extension absent from LH — this extension is heavily glycosylated, giving hCG 8 glycosylation sites versus LH's 3, and is the primary reason for hCG's dramatically extended half-life: 32-33 hours subcutaneous versus LH's approximately 30 minutes intravenous. This pharmacokinetic advantage makes hCG uniquely suitable as a pharmacological LH replacement.

hCG exerts its primary male-relevant effects by binding the LH/CG receptor (LHCGR) on Leydig cells in the testes, triggering cAMP-dependent PKA and PKC signaling that activates CYP11A1 (cholesterol side-chain cleavage enzyme) and drives testosterone synthesis. Crucially, hCG bypasses the pituitary-hypothalamic feedback loop entirely — it stimulates Leydig cells directly regardless of whether the pituitary is suppressed by exogenous testosterone, AAS, or any other hormonal intervention. When exogenous testosterone is administered, serum LH rapidly approaches zero, and intratesticular testosterone (ITT) collapses 90-95% from blood-level concentrations. Since spermatogenesis requires ITT concentrations 50-100 times higher than serum testosterone, 90% of men on TRT without HCG will develop oligospermia or azoospermia within 3-6 months.

In the bodybuilding and performance community, HCG was adopted primarily as a post-cycle recovery tool in the 1980s, used in large blasts (5,000-10,000 IU) after steroid cycles ended. Modern understanding has shifted fundamentally: the preferred approach is now low-dose on-cycle maintenance (250-500 IU 2-3x/week) throughout any suppressive compound protocol, keeping Leydig cells continuously stimulated so testicular degeneration never begins. Running HCG on-cycle prevents the cascade of Leydig cell volume loss, INSL3 collapse, peroxisome decline, and ITT depletion that makes post-cycle recovery harder. The post-cycle blast approach must then try to reverse damage rather than prevent it.

Beyond testicular function, HCG stimulates LHCGR on adrenal gland cells, driving DHEA, DHEA-S, pregnenolone, and pregnenolone sulfate production. These neurosteroids contribute substantially to the subjective wellbeing and libido improvements many users attribute specifically to HCG. Men on testosterone-only TRT who add HCG often describe a qualitatively different libido improvement that testosterone alone could not provide — the neurosteroid component is the explanatory mechanism. This adrenal stimulation is detectable at doses as low as 250 IU three times per week. Over 28,000 studies reference hCG on PubMed, making it among the most-researched gonadotropins in medical literature.

Observed Effects

Testicular Volume: On-cycle HCG maintenance at 250-500 IU 2-3x/week prevents testicular atrophy in the vast majority of AAS users — volume maintained at pre-cycle baseline.

When starting HCG after atrophy has already developed, testicular volume visibly returns within 1-2 weeks.

Testosterone Output: HCG monotherapy in hypogonadal men produces testosterone in the 400-800 ng/dL range in responsive patients; response depends entirely on residual Leydig cell reserve. When used alongside TRT to stimulate testicular output, HCG adds the component of testicular testosterone that exogenous testosterone suppresses — the 'missing' intratesticular and local production.

Semen Parameters: HCG 1,500-3,000 IU three times weekly for 6-12 months restores sperm production to normal spermia levels in most men with TRT-induced azoospermia. Practitioner data: 1,000 IU recombinant hCG three times weekly for over one year produced 73 million sperm/mL with good motility and morphology despite continuous steroid use. The Matsumoto et al. 1983 study demonstrated testosterone and sperm production at 5,000 IU urinary hCG three times weekly in men made oligospermic by 200 mg testosterone enanthate weekly.

Neurosteroids (DHEA, Pregnenolone): DHEA, DHEA-S, pregnenolone, and pregnenolone sulfate all rise with HCG use due to adrenal LHCGR stimulation. This effect is observed at 250 IU 3x/week. Around 500 IU 3x/week, serum testosterone production may plateau (maximum Leydig cell output) while estradiol continues rising and neurosteroid levels continue improving — suggesting different dose-response curves for each downstream effect.

Libido: Libido improvement from HCG is often rapid and subjectively distinct from testosterone effects. A common low-dose pattern is 250 IU EOD producing a noticeable libido change within days, consistent with combined neurosteroid and testosterone effects acting together.

LH/FSH Bloodwork Note: Standard LH immunoassays cross-react with hCG — men using HCG will show artificially elevated 'LH' readings on routine blood panels. True endogenous LH cannot be distinguished from hCG stimulation by standard assay. This is not a safety concern but means LH cannot be used as a meaningful monitoring marker during HCG use.

Field Reports

On-cycle TRT maintenance user runs out of HCG for 2 weeks Outcome: Testosterone reportedly fell to 175 ng/dL within 2 weeks, with depression, weakness, and poor training performance.

A short 1,000 IU daily reloading run restored the prior state within days. Lesson: HCG-dependent protocols carry supply disruption risk. Keep vial inventory ahead of the calendar; interruption can matter quickly when Leydig stimulation is part of the baseline.

Long-term steroid user with continuous HCG use Outcome: Semen parameters reached 73 million sperm/mL with good motility and morphology despite continuous steroid exposure while using recombinant HCG for more than a year. Semen was also banked for future IVF use. Lesson: Continuous HCG can preserve fertility markers in some heavily suppressed men, but semen analysis is the proof. HCG support does not remove the need for banking, fertility labs, or FSH/HMG escalation when counts stall.

3 weeks on HCG — early response pattern Outcome: Testicular volume returned within 1-2 weeks, testosterone moved upward, estradiol rose, and wellbeing improved. Lesson: Volume response can be fast; estradiol response can be fast too. Sensitive E2 testing should happen early after starting or changing dose, even when symptoms are not dramatic yet.

3 months on HCG monotherapy — mixed results Outcome: Testosterone responded, but estradiol rose and mood fluctuated. The user did not have a clear answer on whether monotherapy was sustainable. Lesson: HCG monotherapy is not a simple TRT substitute. It works best when the problem is insufficient pituitary signaling with preserved Leydig reserve; it is frustrating when the limiting factor is testicular reserve or unmanaged E2.

Adding 250 IU HCG EOD to stalled TRT libido protocol Outcome: A low-dose HCG add-on produced rapid libido improvement after testosterone alone had not solved the issue. Lesson: For some men, HCG restores a neurosteroid/libido layer that testosterone does not cover. The dose still needs estradiol follow-up; the point is not to chase libido by escalating blindly.

Fertility protocol with structural testicular issue Outcome: A man on long-term TRT added HCG, later corrected a varicocele surgically, and subsequently had children. Lesson: HCG can optimize hormonal output, but it cannot fix structural fertility barriers. If semen parameters do not improve after months of adequate HCG, investigate varicocele, hydrocele, obstruction, and the need for FSH/HMG.

Protocol evolution from old-school to modern approach Outcome: Older practice leaned on 5,000-10,000 IU post-cycle blasts, while current practice favors lower-dose maintenance or carefully sequenced pre-SERM use. Lesson: More is not better with HCG. The mature read is bullish but bounded: use enough to keep testes responsive, then let labs and the actual goal decide whether to hold, lower, or escalate.

Community Consensus

Adoption: HCG has a settled place in TRT, AAS, fertility, and PCT practice. Community use has moved away from old high-dose post-cycle blasts and toward lower-dose maintenance or structured pre-SERM bridging, because preventing testicular shutdown is usually easier than trying to reverse it after atrophy has set in.

On-cycle vs PCT debate: The strongest consensus favors on-cycle maintenance when fertility, testicular volume, or TRT libido quality matters. The practical argument is simple: 250-500 IU 2-3x/week keeps Leydig cells responsive while suppression is happening; a late blast can restore volume, but it carries more estradiol pressure and starts from a worse baseline.

Monotherapy discussion: HCG monotherapy remains a real but uneven lane. Some pituitary-suppressed men reach normal testosterone and feel good without exogenous testosterone; others plateau, chase estradiol, or discover that primary testicular reserve is the limiting factor. This is an intermediate protocol, not a clean replacement for TRT.

Desensitization awareness: Informed users are cautious about chronic high-dose exposure because the failure pattern is recognizable: the same dose stops producing the same testicular or testosterone response, and dose escalation can make receptor downregulation worse. The practical community lesson is minimum effective dose, lab tracking, and a break or reassessment when response fades.

Access crisis: The 2020 FDA biologic reclassification created a real US supply problem. Pharmaceutical products are quality-controlled but expensive and often packaged for fertility-trigger dosing rather than 250 IU maintenance shots. Long-term users therefore treat sourcing and vial inventory as part of the protocol, not an afterthought.

Neurosteroid narrative: The most useful newer community insight is that HCG can change libido quality through adrenal LHCGR signaling, not just by raising testosterone. That is why DHEA-S, pregnenolone sulfate, estradiol, and subjective libido often need to be interpreted together instead of treating total testosterone as the only endpoint.

Risks & Monitoring

Common: - Estradiol elevation — dose-dependent; at 250 IU 3x/week usually manageable without AI; at 500 IU 3x/week many men require low-dose AI; at 1,000+ IU 3x/week AI co-administration is almost always necessary.

The mechanism is testicular aromatase (CYP19A1) stimulation by hCG, not solely peripheral conversion. - Injection site reactions — mild redness, swelling at subcutaneous injection site; resolved by rotating injection sites - Water retention and bloating at higher doses — secondary to elevated estradiol - Nipple sensitivity / early gynecomastia signs at higher doses without AI — promptly reversible with AI or dose reduction

Occasional: - Acne — proportional to testosterone and estradiol elevation; more common at high doses - Mood fluctuations — estradiol swings can cause mood instability, particularly during dose initiation or changes - Headache — reported at higher doses; mechanism unclear - Scrotal discomfort — when testes rapidly increase in size after atrophy reversal

Rare/Serious: - Leydig cell desensitization — LHCGR downregulation from chronic high-dose use (>2,000 IU frequently, extended periods); in severe cases the desensitization is semi-permanent and hCG loses effectiveness entirely. This is the mechanism behind 'HCG stopped working' presentations. - Gynecomastia development — in estrogen-predisposed men who miss early signs and don't add AI - OHSS (ovarian hyperstimulation syndrome) — relevant only in women receiving hCG in assisted reproduction contexts, not in male bodybuilding use

The fundamental dose-response tension: higher doses give stronger testicular stimulation but drive more estradiol and increase desensitization risk. The practical sweet spot for most men is the lowest dose that achieves the desired endpoint — 250 IU 3x/week for atrophy prevention, 500-1,000 IU 3x/week for fertility goals.

For Women

Monitoring Panels

Avoid With

Protocols By Goal

Testicular atrophy prevention during TRT/AAS. Reported practice commonly uses low repeated weekly hCG exposure from the beginning of suppressive use, with estradiol and symptoms checked after dose changes.

Post-cycle testosterone recovery. hCG is often used before, not concurrently with, SERM-centered recovery because the mechanisms differ. Higher short-term hCG exposure raises the need for estradiol monitoring.

Fertility preservation or recovery. Fertility protocols are months-long and judged by semen analysis, not testicular size alone. If sperm count or motility remains inadequate, FSH or HMG may be added under fertility-oriented care.

Monotherapy. Some men use hCG when pituitary signaling is weak but Leydig-cell reserve is intact. Primary testicular failure is a poor fit.

Women. hCG is used clinically for ovulation triggering and reproductive medicine, not general wellness or performance. Ovarian-stimulation contexts require clinician monitoring.

Dosing Details

Reported hCG use separates several contexts: low-dose on-cycle testicular maintenance, short higher-exposure post-cycle use before SERM-based recovery, fertility protocols lasting months, and monotherapy in selected men with preserved Leydig-cell reserve. Commonly reported male maintenance ranges cluster around 250-500 IU two or three times weekly; fertility-oriented protocols often use higher repeated weekly exposure and add FSH or HMG when semen parameters remain poor.

These are observed clinical/community patterns, not instructions. The central risk is excess Leydig stimulation: estradiol overshoot, gynecomastia, mood swings, and possible desensitization when users push dose instead of measuring response. Semen analysis, testosterone, estradiol, and symptoms should drive interpretation.

The article does not provide reconstitution or injection how-to. hCG is a fertility medication with pregnancy and ovarian-stimulation uses in women, and female use belongs in clinician-managed reproductive protocols because ovarian hyperstimulation is a real risk.

Stacks & Alternatives

Testosterone suppresses endogenous LH and ITT; HCG restores what testosterone suppresses. Standard TRT-plus-HCG is the most common combination in both clinical and underground settings. HCG adds testicular testosterone output, neurosteroids, and fertility preservation that exogenous testosterone alone cannot provide.

HCG stimulates testicular aromatase and drives estradiol elevation dose-dependently. At 500+ IU 3x/week, most men need AI co-administration. Anastrozole 0.25-0.5 mg 2x/week or exemestane 12.5 mg EOD are standard starting points.

HCG covers the Leydig cell (testosterone) axis but cannot stimulate FSH — Sertoli cells and spermatogenesis require FSH. For fertility goals, adding FSH 75 IU 3x/week (or HMG 75 IU 3x/week) to HCG after 3-6 months addresses persistent oligospermia. Modern preference is recombinant FSH over HMG due to more consistent FSH-only activity.

HCG stimulates adrenal neurosteroid production but may be insufficient in older men or those with declining adrenal reserve. Oral DHEA 25-100 mg and/or pregnenolone 25-100 mg supplement what HCG's adrenal stimulation cannot fully restore. This combination targets the neurosteroid component of libido and wellbeing.

After HCG has restored testicular function, SERMs drive central HPT axis recovery by blocking estrogen receptors in the hypothalamus/pituitary, increasing endogenous LH/FSH secretion. This completes the HPT axis restart that HCG alone cannot accomplish.

Alternatives

Stack Cost

Practical Setup

hCG interpretation depends on context. For men, track estradiol sensitive, total testosterone, symptoms, and semen analysis when fertility is the goal.

LH becomes hard to interpret during hCG use because of assay cross-reactivity; FSH remains relevant because hCG has no FSH activity.

The main male mistake pattern is chasing higher hCG exposure when estradiol is already high. If gynecomastia, water retention, mood swings, or libido volatility appear, reducing hCG exposure is often more coherent than adding more estrogen-control medication by default.

For women, hCG belongs in reproductive medicine contexts such as ovulation triggering. OHSS symptoms, pelvic pain, rapid weight gain, shortness of breath, or marked bloating require clinical attention. Public prose should not provide injection setup, compounding access workarounds, or access-route details.

Mechanism Deep Dive

LH Receptor Binding and Leydig Cell Activation hCG binds the luteinizing hormone/choriogonadotropin receptor (LHCGR) on testicular Leydig cells.

The LHCGR is a G-protein coupled receptor — hCG binding activates adenylyl cyclase, raising intracellular cAMP, which activates protein kinase A (PKA). PKA phosphorylates the steroidogenic acute regulatory (StAR) protein, facilitating cholesterol transport into the mitochondria where CYP11A1 cleaves the side chain to produce pregnenolone, the precursor to testosterone. hCG is structurally bioidentical to LH at the LHCGR — the receptor cannot distinguish exogenous hCG from endogenous LH by molecular recognition. The critical difference is pharmacokinetic: hCG's 32-33 hour half-life (vs LH's ~30 minutes) provides sustained Leydig cell stimulation from 2-3 weekly injections rather than the episodic pulsatile LH pattern the pituitary would normally produce.

Testicular Aromatase Stimulation and Estradiol Elevation hCG stimulates not just testosterone synthesis but also CYP19A1 (aromatase) expression and activity on Leydig cells. Testicular aromatase converts testosterone to estradiol within the testes — this is the primary mechanism of estradiol elevation during HCG use. This effect is dose-dependent and is distinct from peripheral (adipose tissue) aromatization of circulating testosterone. At approximately 500 IU 3x/week, testosterone production appears to plateau (maximum Leydig cell output reached) while estradiol continues rising — consistent with aromatase activity continuing to scale with hCG dose beyond the testosterone production ceiling. This dissociation between testosterone plateau and continued E2 rise is the mechanistic basis for using the lowest effective HCG dose rather than maximizing dose.

Why Standard LH Blood Tests Show False Results During HCG Use Standard clinical LH immunoassays use antibodies that cross-react with hCG due to the structural homology of their shared alpha subunit and beta subunit similarities. A man using exogenous hCG will show elevated 'LH' on routine blood panels — but this reading reflects hCG, not endogenous pituitary LH. True endogenous LH is suppressed to near-zero by exogenous testosterone while hCG runs simultaneously. This immunoassay cross-reactivity means LH cannot be used as a meaningful monitoring marker during HCG use. FSH is interpretable (hCG has no FSH-like activity). If distinguishing true LH from hCG is clinically necessary, hCG-specific assays exist but are not routinely ordered.

Structural Homology to LH: The Pharmacological Foundation hCG and LH share an identical alpha subunit (92 amino acids). The beta subunit of hCG is 80-85% homologous to LH's beta chain with one key addition: a 24-amino-acid carboxy-terminal extension. This extension contains additional glycosylation sites — hCG has 8 glycosylation sites total versus LH's 3. The carbohydrate moieties protect the protein from rapid renal clearance and reduce metabolic inactivation rate. The result: subcutaneous hCG half-life of 32-33 hours versus LH's approximately 30-minute IV half-life. This structural difference has no functional consequence at the receptor level but is everything pharmacokinetically.

Adrenal LHCGR Stimulation and Neurosteroid Production The LHCGR is expressed not only in the gonads but also in the adrenal cortex. Exogenous hCG stimulates adrenal LHCGR, driving production of DHEA, DHEA-S, pregnenolone, and pregnenolone sulfate from the adrenal glands. This neurosteroid output is detectable at doses as low as 250 IU three times per week. These neurosteroids contribute to the subjective wellbeing and libido quality improvements many users attribute to HCG. When exogenous testosterone suppresses the HPT axis, ACTH-driven pathways remain intact for basic adrenal function, but the LHCGR-dependent neurosteroid production collapses without LH/hCG stimulation. Restoring hCG restores this adrenal neurosteroid output — the 'HCG feeling' that many users describe is mechanistically distinct from testosterone's androgenic effects.

Why Desensitization Occurs at High Doses Chronic supraphysiological hCG stimulation causes LHCGR internalization via receptor downregulation — the standard G-protein coupled receptor response to sustained agonist stimulation. Receptor density on Leydig cells decreases, reducing the steroidogenic response to subsequent hCG doses. This manifests clinically as testes that continue to shrink despite HCG use or testosterone that gradually declines at the same dose. The paradox: increasing the dose at this point accelerates rather than reverses desensitization. Prevention requires using the minimum effective dose rather than maximizing dose.

Evidence Index